Tradestie Institutional Equity Comparison Engine

ABVC vs DUKX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ABVC Overall Edge

ABVC Captures Institutional Edge (1โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ABVC BioPharma, Inc. Common Stock (ABVC) driven by superior Growth & Margin while DUKX counters with relative strength in Momentum & Technical. Fundamentally, ABVC trades at N/M Forward P/E with 0.0% operating margin (+104.5% YoY revenue) versus DUKX at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ABVC sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against DUKX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ABVC N/M vs DUKX N/M Fwd P/E
Growth & Margin Winner ABVC
Op Margin 0.0% vs N/A ยท YoY +104.5% vs N/A
Momentum & Technical Winner DUKX
1Y -66.4% vs +2.5% ยท 52W Pos 10% vs 35%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
ABVC NASDAQ
ABVC BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$0.94
+3.3% 1D
Market Cap $24.5M
1M Return +2.41%
1Y Return -66.43%
Forward P/E N/M
Unified AI Score
39.4 / 100 SELL
Tech 32.0 Fund 39.0 Flow 50.0 Mom 40.0
DUKX NASDAQ
Ocean Park International ETF
Institutional Equity
$26.62
-1.85% 1D
Market Cap N/A
1M Return -4.32%
1Y Return +2.49%
Forward P/E N/M
Unified AI Score
51.6 / 100 HOLD
Tech 50.0 Fund 52.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ABVC -66.43% DUKX +2.49% Spread: +68.92 pp (DUKX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ABVC TTM Op. Margin: 0.0% DUKX TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABVC vs DUKX. Trailing 12-month operating profitability (ABVC 0.0% vs DUKX N/A) and valuation multiples (ABVC N/M vs DUKX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ABVC (5) vs DUKX (3)
Institutional Metric ABVC DUKX Criterion Row Winner
Market Capitalization Scale $24.5M N/A Larger Scale ABVC
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +104.5% N/A Higher Growth ABVC
Operating Margin (TTM) Profitability 0.0% N/A Higher Margin ABVC
Net Profit Margin Profitability 0.0% N/A Higher Margin ABVC
Return on Equity (ROE) Capital Efficiency -52.7% N/A Higher ROE ABVC
52-Week Range Position Momentum 10% ($1โ€“$3) 35% ($25โ€“$29) Stronger Trend DUKX
Beta / 30D Volatility Risk Regime 1.34ฮฒ ยท 56% Vol 0.94ฮฒ ยท 21% Vol Lower Realized Risk DUKX
Unified Institutional Score Composite Signal 39.4 / 100 (SELL) 51.6 / 100 (HOLD) Higher Composite DUKX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ABVC vs DUKX Buy Guide
ABVC UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live ABVC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DUKX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live DUKX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ABVC nor DUKX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.